What is the study about?

While often more subtle than positive and negative symptoms, cognitive impairment associated with schizophrenia (CIAS) affects nearly everyone living with the condition. Currently, there are no approved drugs to treat these cognitive symptoms. Tally is a new clinical trial that aims to understand if an investigational drug could be effective in impacting the lives of people with schizophrenia who experience cognitive difficulties.

Who can take part?

If you have a diagnosis of schizophrenia and are aged 18 to 55, or know someone is and who might benefit from this research please get in touch.

What is involved?

Participants will be randomly assigned to receive either an active drug or placebo. During the duration of the trial (20 weeks) they will be required to visit the clinic about every 2 weeks to complete physical and cognitive tests. All travel and food expenses are covered.

How do I get involved?

If you are interested in the study or would like more information please contact the Research and Development Department, on 01932 722247 or email research@sabp.nhs.uk